Baclofen

Baclofen is a GABA-B receptor agonist that was developed in the 1960s as a muscle relaxant for spasticity in multiple sclerosis and spinal cord injury. It's the same family of receptor that alcohol, GHB, and phenibut hit, which is why baclofen has quietly become one of the most studied pharmaceutical tools for reducing alcohol craving, anxiety, and other behaviours that ride the same reward circuitry.

Most people exploring it outside of muscle spasticity are using it for one of three things: cutting alcohol intake (this is by far the strongest evidence base), calming background anxiety without the dependence profile of benzodiazepines, or controlling reflux that hasn't responded to standard PPI treatment. It's not a recreational compound and it doesn't produce euphoria. What it does is dial down the urgency of cravings, intrusive thoughts, and the autonomic edge that drives compulsive behaviour. People who respond well often describe it as the volume knob on the part of their brain that won't shut up.

Deep-dive

Baclofen selectively activates the GABA-B receptor, a G-protein coupled receptor that sits both pre- and postsynaptically across the central nervous system. Activation does two things: it opens potassium channels (hyperpolarising the neuron and making it less likely to fire) and it inhibits calcium channels (reducing neurotransmitter release at the presynaptic terminal). The net effect is suppression of excitatory output, particularly glutamate, dopamine, noradrenaline, and serotonin release in regions where these are firing hard. This is mechanistically distinct from GABA-A agonists like benzodiazepines, alcohol, and Z-drugs, which is why baclofen doesn't produce the same euphoria or amnesia and doesn't share the same addiction profile, though it has its own withdrawal syndrome that's covered below. A detailed receptor pharmacology review lays out the full pre- and postsynaptic action.

The oral bioavailability is relatively high, plasma peak occurs in roughly an hour, and the elimination half-life sits at about 3 to 6 hours in healthy adults, which is why dosing is split across the day. Around 70 to 85% of the drug is excreted unchanged by the kidneys, so kidney function matters a lot for how this compound behaves in your body. This is the single most important pharmacokinetic detail to know, particularly as you age.

Alcohol use disorder. This is where baclofen has its strongest non-spasticity evidence base. The original case that put it on the map was the cardiologist Olivier Ameisen, who used high-dose baclofen on himself to suppress his own alcohol cravings and wrote about it in 2008. Since then, a 2018 clinical practice review summarises 15 randomised controlled trials, with most using fixed doses of 30 to 80 mg/day and some titrating up to 300 mg/day. A 2021 US dose-response trial compared 30 mg/day, 90 mg/day, and placebo over 16 weeks. The 90 mg/day group showed 13.6 fewer heavy drinking days and 12.9 more abstinent days than placebo, with effect sizes (d = 0.39 to 0.47) that are larger than what naltrexone or acamprosate typically deliver. A 2025 systematic review and dose-response meta-analysis of 14 trials and 1,344 patients found benefits on percent days abstinent and craving up to 50 to 60 mg/day, with diminishing tolerability above that. The compound also works in a population that other AUD drugs can't safely treat: the Addolorato 2007 Lancet trial tested baclofen in alcohol-dependent patients with established liver cirrhosis, where naltrexone is contraindicated and acamprosate's safety isn't established. 71% of baclofen patients achieved abstinence versus 29% on placebo over 12 weeks. This makes baclofen functionally the only well-evidenced anticraving drug for people with serious alcohol-related liver damage.

The mechanism in addiction isn't fully nailed down. A 2018 review proposes that baclofen suppresses the Pavlovian link between cues and reward by acting on GABA-B receptors in the amygdala, normalising the dopaminergic reward network. Imaging studies show baclofen produces region-specific changes in cerebral activity that overlap with regions affected by alcohol itself. Whatever the exact pathway, the practical outcome is reduced craving, reduced anxiety around drinking, and in responders, indifference to alcohol that previously felt compulsive.

Anxiety. Baclofen's anxiolytic effect is part of why it works for AUD (anxiety drives drinking), but it's also relevant on its own. GABA-B receptor activation in the limbic system reduces the autonomic and subjective components of anxiety. Unlike benzodiazepines, baclofen doesn't significantly impair memory or coordination at therapeutic doses and doesn't produce the same tolerance escalation. It is, however, sedating, and that's the dose-limiting side effect for most people.

Reflux (GERD). Baclofen reduces transient lower oesophageal sphincter relaxations (TLESRs), which are the primary mechanism behind reflux episodes. A 2014 meta-analysis of 9 trials found baclofen reduced the number and length of reflux episodes and the incidence of TLESRs versus placebo. A 2022 systematic review of 26 studies concluded that adding baclofen to a PPI in PPI-resistant GERD patients can meaningfully improve symptoms, with side effects in under 5% of short-term users and around 20% of long-term users. It's particularly worth considering for people with non-acid reflux, hiatal hernia, or concurrent alcohol use disorder, where the mechanism overlap matters.

Cocaine and other addictions. A 2003 randomised trial showed early signal for cocaine craving reduction. The effect is smaller and less consistent than for alcohol, but the same anti-Pavlovian-cue mechanism appears to apply across reward-driven behaviours. There's emerging interest in gambling and binge-eating contexts, but the controlled data is thinner.

Sleep. Baclofen increases slow-wave (deep) sleep at moderate doses, which is part of why people often report unusually vivid dreams or feeling unrested at first. This effect typically settles within a couple of weeks.

Women. Sex differences in baclofen response are real and matter for dosing. A 2021 dose-response trial found women responded best at 30 mg/day for alcohol use disorder, with strong effects on heavy drinking days (26.3 fewer than placebo) and abstinent days. At 90 mg/day, women showed similar efficacy but 59% dropped out or had to reduce dose because of sedation, compared with 5% of men. Men in the same trial showed the opposite pattern: marginal effect at 30 mg/day, best response at 90 mg/day. A 2022 secondary analysis confirmed sex as a moderator of baclofen response, with women generally getting more benefit at lower doses but more side effects at higher ones. The probable explanation is body water distribution and kidney handling, the same factors that explain why women hit higher blood alcohol concentrations from the same drink. The practical takeaway: women should start lower and titrate slower, and many find that 30 to 50 mg/day delivers the full effect with much less sedation than men typically need to achieve the same result.

Older adults. Baclofen accumulates in people with reduced kidney function, which becomes a real concern from late middle age onward even in apparently healthy people. A case series in the American Journal of Kidney Diseases recommends reducing the dose at eGFR 30 to 60 mL/min/1.73m² and avoiding it entirely below eGFR 30. A geriatric pharmacology study found older adults with chronic kidney disease are particularly vulnerable to confusion and encephalopathy at standard doses. AGS guidelines recommend a 15 mg/day maximum in older adults with persistent pain, with attention to fall risk. If you're over 60, check eGFR before starting and dose conservatively.

Limitations of the evidence. AUD trial results are mixed across studies. Some have failed to find a baclofen advantage over placebo, particularly in less severe drinkers or at low fixed doses. The trials that show the strongest effects tend to use higher doses, longer treatment, more severe AUD populations, or both. There's no consensus on optimal dose or duration. Most studies run 12 to 16 weeks, so long-term efficacy and tolerance data is limited. The compound has clearly worked for some people and clearly not worked for others, and there's no validated way to predict who will respond before trying it.

Dosage:

Spasticity (the on-label use): Start at 5 mg three times daily. Titrate up by 5 mg per dose every 3 days based on response and tolerance. Typical effective range is 30 to 80 mg/day in 3 or 4 divided doses. Maximum on-label is 80 mg/day, though higher doses are routinely used off-label

Alcohol use disorder: Start at 5 to 10 mg three times daily. Titrate up by 10 to 20 mg every few days. Most evidence supports 30 to 80 mg/day in divided doses. Higher-dose protocols (up to 200 to 300 mg/day) exist for resistant cases under specialist supervision. Women generally respond best at 30 to 50 mg/day; pushing higher tends to cause sedation that outweighs benefit. Men typically need 60 to 90 mg/day for full effect

Anxiety (off-label): 10 to 30 mg/day in divided doses is usually enough. Start low (5 mg twice daily) to gauge sedation

Reflux (off-label adjunct to PPI): 10 to 20 mg three times daily, taken before meals. Lower doses are often effective and better tolerated

Timing: Split doses across the day because of the short half-life. Three times daily is standard. Take the largest dose at bedtime if sedation is a problem (this also captures the slow-wave sleep benefit)

With food: A high-fat meal modestly reduces peak concentration but doesn't meaningfully change total absorption. Take with or without food, whichever produces less GI upset for you

Kidney function: Reduce dose at eGFR 30 to 60 mL/min/1.73m². Avoid below eGFR 30. Older adults should start at 5 mg twice daily regardless of stated kidney function and titrate slowly

Tapering: Never stop abruptly. Reduce by 5 to 10 mg per week, slower at higher starting doses. Abrupt cessation can cause severe withdrawal including seizures, hallucinations, and a syndrome resembling neuroleptic malignant syndrome

Here's what you can expect:

The most important thing to understand is that baclofen is a chronic compound, not an acute one. The benefits people actually want from it (reduced craving, reduced background anxiety, reduced reflux) are built up over weeks of consistent dosing as GABA-B tone shifts. A single dose mostly gives you the side effects without the upside.

Single dose (10 to 20 mg). You'll feel something within 60 to 90 minutes: physical heaviness, mild sedation, slight muscle looseness, and for some people a flat calming of background anxiety. But it's not a clean anxiolytic the way a benzodiazepine or phenibut is. The calm is a side effect of the general CNS depression, not a targeted hit on the worry circuits. Most people describe a single dose as feeling tired, slightly clumsy, and a bit detached, with the anxiety reduction muddied by the sedation. Some people get nothing subjective at all from a single dose. It is not a recreational compound and won't produce euphoria. If you're looking for on-demand anxiety relief for a specific moment (presentation, flight, social event), baclofen is a poor tool.

Building tolerance to sedation (week 1 to 2). During titration, the first few days are usually the roughest. Drowsiness, mild dizziness, and a slightly fuzzy or detached feeling are common while your nervous system adapts. Vivid dreams and feeling unrested even after a long sleep are also common; this is the slow-wave sleep increase settling in. Most people adapt within one to two weeks if the dose isn't pushed too fast.

Anxiety (week 2 to 4). Once you're past the initial sedation, the actual anxiolytic effect emerges as a quieter baseline. Background tension drops, racing thoughts settle, and the autonomic edge (tight chest, restlessness, low-level alertness) eases. It's a different kind of relief than benzodiazepines: less acute, more flat, but without the cognitive dulling and without the dependence escalation. The effect is on chronic anxious tone, not acute panic.

Alcohol craving (week 2 to 4). Once at an effective dose, the effect on craving usually shows up within 2 to 4 weeks. In responders, the change is striking: alcohol stops feeling interesting, and the mental loop that normally drives drinking quietens. People often describe it as alcohol becoming neutral rather than rewarding. In non-responders, you'll know by week 6 to 8 if it isn't working.

Reflux (a few days to 4 weeks). Expect to start noticing fewer episodes within days, with full effect by 2 to 4 weeks. Works best as an add-on when PPIs alone aren't cutting it.

What baclofen doesn't do: it doesn't get you high, it doesn't motivate you, it doesn't sharpen cognition, and it doesn't deliver acute anxiety relief on demand. The compound's value is in what it removes (chronic craving, chronic anxiety, reflux) not what it adds, and only with consistent dosing over weeks.

Side effects & risks:

Sedation and drowsiness are the most common side effects, especially during titration. Usually settles within 1 to 2 weeks at a stable dose. Don't drive until you know how you respond. Women are more sensitive to sedation than men at equivalent weight-adjusted doses

Dizziness, fatigue, weakness, and nausea are also common in the first weeks. Usually dose-dependent and resolve with slower titration or dose reduction

Cognitive effects including poor concentration, recall problems (sometimes described as a mild dementia-like state at high doses), and slowed processing. More pronounced in older adults and people with reduced kidney function

Vivid dreams and disrupted sleep architecture in the first few weeks. The slow-wave sleep increase is generally considered beneficial long-term but can be subjectively unpleasant initially

Withdrawal is the most serious risk and the one to take seriously. Abrupt discontinuation, especially after long-term or high-dose use, can cause hallucinations, seizures, severe rebound spasticity, fever, autonomic instability, and a syndrome that mimics neuroleptic malignant syndrome. Case reports describe deaths from abrupt cessation. Always taper. Keep extra supply on hand so a missed prescription refill doesn't trigger withdrawal

Kidney function is the main long-term safety concern. Baclofen is renally excreted, and accumulation in CKD can cause encephalopathy, confusion, and respiratory depression even at standard doses. Multiple case reports describe neurotoxicity in patients with previously unrecognised kidney impairment. Get baseline renal function before starting and recheck annually, more often if you're over 60 or have any cardiovascular or metabolic risk factors

Dependence potential is real but different from benzodiazepines. Baclofen doesn't produce euphoria and isn't typically misused for its own sake, but physical dependence develops with regular use. People with a history of substance use disorder using baclofen for AUD are still at risk of misusing it, particularly at higher doses

CNS depressant interactions: Major caution with alcohol, opioids, benzodiazepines, Z-drugs, gabapentinoids, sedating antihistamines, and any other CNS depressant. Combining can cause respiratory depression. This is particularly relevant given that many baclofen users are also drinking, even if reduced amounts

Tricyclic antidepressants can potentiate baclofen's effects and worsen sedation

Pregnancy and breastfeeding: Baclofen crosses the placenta and is present in breast milk. Use only if benefit clearly outweighs risk, and not at high doses

Liver: Baclofen is largely renally cleared and has not been linked to clinically significant liver injury at therapeutic doses. It's one of the few anticraving drugs considered safe in established liver disease, including cirrhosis

Overdose can cause coma, respiratory depression, seizures, hypotension, and bradycardia. Severe overdose may require ICU admission and dialysis. The therapeutic index is wider than benzodiazepines but narrower than many people assume

🩸

Blood markers

eGFR and creatinine, baseline and at least annually if you're using baclofen long-term, more often if you're over 60. This is the single most important marker. Reduced kidney function is what turns a routine dose into a toxic one. Stop or substantially reduce the dose if eGFR drops below 60, and avoid baclofen entirely below 30.

Liver function (ALT, AST, GGT) baseline if you're using baclofen for alcohol use disorder, since you likely have alcohol-related liver concerns to begin with. Recheck at 3 months and then every 6 to 12 months. Baclofen itself doesn't damage the liver but the underlying drinking might.

Blood pressure, baseline. Baclofen can lower BP modestly, particularly during titration. Worth knowing your starting point if you're already on antihypertensives or other compounds that affect BP.

Full blood count and electrolytes are reasonable as part of a baseline panel but aren't specifically driven by baclofen unless you have other indications.

Most people using baclofen short-term at standard doses with normal kidney function don't need ongoing specialist monitoring. The people who actually need careful follow-up are anyone over 60, anyone with established or borderline kidney disease, anyone using doses above 80 mg/day, and anyone using baclofen alongside other CNS depressants. If you fall into any of those groups, don't run this without a clinician you can call.

Prescription medication in most countries; off-label use for alcohol use disorder, anxiety, and reflux is well-established but unlicensed in many jurisdictions.